What type of receptor does Eluxadoline (Viberzi) act on besides mu receptors?

Eluxadoline (Viberzi) primarily acts on the mu-opioid receptors, but it also has activity at kappa receptors. This interaction with the kappa receptors is significant because kappa-opioid receptor agonism can lead to analgesic effects and is associated with a different side effect profile compared to mu receptor activation. The relevance of kappa receptors in the mechanism of action for Eluxadoline enhances its therapeutic potential in managing certain gastrointestinal conditions by modulating pain and providing relief from symptoms associated with irritable bowel syndrome with diarrhea (IBS-D).

Understanding the role of kappa receptors is essential in pain management, as they can provide analgesic benefits without some of the addictive potential associated with mu receptor agonists. The other receptors listed, such as delta, serotonin, and GABA receptors, do not play a direct role in the pharmacological profile of Eluxadoline in the same way kappa receptors do. This makes the connection with kappa receptors particularly important for healthcare professionals dealing with opioid analgesics and pain management strategies.